Huntington’s Disease Tablet Formulation for HTT mRNA Splicing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Huntington's Disease (HD) only manage symptoms and do not slow the progression of the disease, with no approved therapeutics available to modify the disease course.
Innovation Solution
A tablet formulation containing 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol (Compound 1) as an active ingredient, combined with specific excipients, is developed to potentially slow the progression of HD by reducing HTT production and altering mRNA splicing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current symptomatic therapies are used for Huntington's Disease, then symptom management is achieved, but disease progression cannot be slowed
Solution Approach 1:
The patent applies parameter changes by modifying the splicing pattern of HTT mRNA through small molecule compound intervention. The compound alters the molecular parameters of mRNA processing to produce an in-frame stop codon, thereby changing the biological outcome from progressive disease to disease modification without requiring complex manufacturing processes
Solution Approach 2:
The patent uses small molecule compounds as intermediaries to mediate between the HTT gene and the resulting protein production. These compounds act as splicing modulators that intervene in the mRNA processing pathway, serving as a bridge to achieve disease modification through a manageable therapeutic mechanism
2Reliability
If small molecule disease-modifying therapies are developed, then disease progression can be slowed, but manufacturing and formulation complexity increases
Solution Approach 1:
The patent utilizes parameter changes in the molecular structure of small molecule compounds to achieve disease modification. By designing compounds with specific structural parameters that target splicing machinery, the patent achieves therapeutic effect through relatively simple molecular entities that can be formulated as standard tablets
Solution Approach 2:
The patent applies local quality by designing small molecule compounds with specific functional groups and structural features localized to interact with splicing components. This targeted local molecular design achieves disease modification without requiring complex overall formulation structures
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present description relates to a tablet formulation of 2-[3-(2,2,6,6- tetramethylpiperidin-4-yl)-3H-[l,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-l,2,3-triazol-2- yl)phenol, a compound for use in treating Huntington's disease, and a method of making the same.